Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreCISeRT: Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer
NCT05182112Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose of Focal Simultaneously Integrated Boost at 1 year. Started Dec 2021; status: completed.
Beyond the preview
Go deeper on NCT05182112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182112.